Organisation paid for research Program year 2025 Source: CMS Open Payments

Wallace Medical Group Inc

Neither a doctor nor a teaching hospital

Research payments

$4,425,257

186 payments

Through program year 2025, Wallace Medical Group Inc is reported as receiving $4,425,257 in research payments, across 186 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $717,292 31
2024 Research $1,072,540 42
2023 Research $380,095 25
2022 Research $719,400 27
2021 Research $916,091 31
2020 Research $258,985 26
2019 Research $360,854 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,034,558 36 payments
  2. Pfizer Inc. $966,141 108 payments
  3. Amgen Inc. $739,073 10 payments
  4. Janssen Research & Development, LLC $610,646 22 payments
  5. AbbVie, Inc. $51,535 8 payments
  6. Horizon Therapeutics plc $23,304 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $530,294 3 payments
  2. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $498,677 3 payments
  3. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $381,574 14 payments
  4. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $358,573 3 payments
  5. A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $328,905 17 payments
  6. ASCEND P3 AD Extension $278,298 2 payments
  7. A Phase 2a2b Multi Center Randomized Placebo and Active Comparator controlled Double Blind Dose ranging Study to Evaluate the Safety and Efficacy of Bermekimab JNJ77474462 for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa. $229,072 8 payments
  8. A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Non Segmental Vitiligo $224,300 25 payments
  9. A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $224,006 2 payments
  10. A Phase 3B Randomized Doubleblind Doubledummy Active Controlled Multicenter Study Assessing the Efficacy and Safety of Abrocitinib Compared With Dupilumab in Adult Participants on Background Topical Therapy With Moderate to Severe Atopic Dermatitis $167,655 31 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record